SELLAS Life Sciences Group, Inc. has filed a $150 million at-the-market follow-on equity offering alongside a broad shelf registration covering various securities. This comes after they reported a narrower full-year net loss of $26.86 million for 2025, alongside promising preclinical data for their CDK9 inhibitor SLS009 in acute myeloid leukemia (AML), particularly in mutation-heavy models. While the preclinical results support the potential of SLS009, concerns remain over SELLAS’s reliance on equity markets for financing amid ongoing operational losses and a recent 8.30% decline in share price. Valuations vary widely, indicating differing investor expectations about the company’s future amidst its financing-heavy model.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-sls/sellas-life-sciences-group/news/why-sellas-life-sciences-group-sls-is-down-83-after-us150-mi
